PhotoCure ASA - Hexvix recommended for diagnosis of bladder cancer
Oslo, Norway, 19 September 2005. Blue light fluorescence cystoscopy, such as PhotoCure's Hexvix, is recommended by the European Association of Urology in newly developed guidelines for diagnosis and treatment of urothelial carcinoma in situ (CIS). The guidelines also recommend that CIS be regarded as highly malignant. The guidelines were published in the September issue of the scientific journal European Urology. "The inclusion of Hexvix in the European guidelines is an endorsement of the medical benefits of our technology and will greatly increase knowledge of our product as it is